– ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear palsy – – ARV-102 was well tolerated across all dose levels following 28 days of once-daily dosing – – Data support further development of ARV-102 in additional neurodegenerative diseases characterized by lysosomal dysfunction, including progressive supranuclear palsy, a rapidly progressing and devastating tauopathy – – Data presented during an oral session at the Alzheimer’s and P ...

– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease – NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease (PD) will be presented at the 2026 International Confe ...

Core Insights - Arvinas is transitioning into a Phase 1 company with 4 programs currently in Phase 1 clinical trials as of early 2026 [2][3] - The company has developed a LRRK2 degrader for neurodegenerative disorders and a KRAS G12D degrader for solid tumors [2] - A BCL6 degrader for hematology is also in development, along with a new clinical trial for a program targeting AR, specifically for Kennedy's disease [3] - The previously leading program, Vepdegestrant, has shown positive pivotal data and an NDA has been filed with the FDA, with a PDUFA date set for early June [4]

Summary of Arvinas Conference Call Company Overview - **Company**: Arvinas - **Industry**: Biotechnology - **Focus**: Development of targeted protein degraders (PROTACs) for various diseases, including neurodegenerative disorders and cancers Key Points and Arguments Current Pipeline and Programs - Arvinas has four programs in Phase 1 as of 2026, including: - LRRK2 degrader for neurodegenerative disorders - KRAS G12D degrader for solid tumors - BCL6 degrader for hematology - A new program targeting AR for Kennedy's disease, recently initiated [2][3][4] Vepdegestrant Program - The previously leading program, vepdegestrant (an ER degrader), has positive pivotal data and an NDA filed with the FDA, with a PDUFA date in early June [3][8] - The company is actively seeking partnerships for this program, with discussions progressing well [8] LRRK2 Program Insights - The LRRK2 program (ARV-102) is expected to provide data soon, with a focus on its role in Parkinson's disease and progressive supranuclear palsy [10][12] - Preclinical data shows increased lysosome number and capacity, indicating potential benefits for patients [11] Differentiation Strategy - Emphasis on creating differentiated clinical candidates and ensuring the right use of technology [6] - The company aims to leverage its PROTAC platform to develop unique therapies that outperform existing treatments [5] KRAS Program - The KRAS G12D degrader (ARV-806) is noted for its ability to remove the oncoprotein from tumors, showing 25-fold greater potency than existing clinical mechanisms [47] - The program is designed to avoid the rapid resynthesis of the oncoprotein seen with inhibitors, aiming for durable degradation [50][60] - Initial data readouts will focus on safety and potential efficacy, with a need to differentiate from competitors [59][60] BCL6 Program - The BCL6 degrader (ARV-393) is in Phase 1, with data expected in the second half of the year [75] - The program will explore both monotherapy and combination studies, particularly with glofitamab [80] Market Opportunity - Progressive supranuclear palsy is highlighted as a rare but significant market, with approximately 25,000 diagnosed patients in the U.S. [42] - The company is positioned to address unmet needs in both neurodegenerative diseases and oncology, with a focus on innovative treatment approaches [39][40] Future Development and Partnerships - The company is open to partnerships for advancing its programs, especially in competitive areas like KRAS [70] - Plans to start a Phase 1b trial in patients with progressive supranuclear palsy within the year [32] Additional Important Content - The company is committed to ensuring that its therapies are available to patients as soon as possible upon FDA approval [8] - The focus on differentiation and the potential for combination therapies is critical for success in a crowded market [60][70] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Arvinas' commitment to innovation in biotechnology and its proactive approach to navigating competitive landscapes.

Investment Rating - The report suggests a positive investment outlook for the targeted protein degradation (TPD) industry, indicating it is at a historical turning point for commercialization, with significant growth potential similar to the ADC sector [1]. Core Insights - The TPD field is transitioning from a scientific concept to a commercial explosion, with key catalysts expected in 2026, including the approval of Arvinas' ARV-471 and BMS's Iberdomide, marking the realization of TPD technology's value after over 20 years of development [1]. - The report highlights the dual-driven technological landscape of PROTAC and molecular glue, with rapid penetration into new therapeutic areas such as autoimmune diseases, showcasing the industry's adaptability and growth potential [2]. - The emergence of AI technologies is accelerating the drug development process in TPD, making this an optimal time for investment as the first PROTAC molecules are set to commercialize [17]. Summary by Sections Investment Logic - TPD is expected to replicate the growth trajectory of ADCs, overcoming barriers associated with traditional small molecule inhibitors by utilizing the UPS and ALPS systems for effective protein degradation [1]. - 2026 is projected to be a pivotal year for commercialization, with significant drug approvals anticipated [1]. Technological Pathways - The report outlines a dual-driven approach with PROTAC and molecular glue technologies, emphasizing their clinical validation and the potential for new therapeutic applications [2]. - The self-immune field is highlighted as a strategic growth area, with companies like Kymera and Monte Rosa developing promising candidates [2]. Competitive Landscape - Key catalysts in 2026 are expected to reshape the competitive landscape, with companies demonstrating platform capabilities and differentiated target strategies likely to enjoy valuation premiums [3]. - The report identifies several leading companies and their promising pipelines, including Arvinas, Nurix, and Monte Rosa, which are positioned to capitalize on upcoming clinical data and market opportunities [3]. Investment Recommendations - The report recommends focusing on late-stage assets nearing commercialization, particularly those from Arvinas and BMS, while also highlighting biotech firms like Monte Rosa and Kymera that are expanding into autoimmune and chronic disease markets [4].

Summary of Arvinas Conference Call Company Overview - **Company**: Arvinas (NasdaqGS:ARVN) - **Focus**: Development of PROTAC degraders, with four programs currently in phase one across various disease areas [5][6] Key Programs and Developments - **Pipeline**: - **Vepdegestrant**: Positive pivotal phase trial readout for ER degrader [6] - **Bavdegalutamide**: Outlicensed to Novartis, providing a strong foundation for future growth [6] - **ARV-102**: LRRK2 degrader targeting neurodegeneration, showing promise in reducing LRRK2 levels in cerebrospinal fluid [39][40] - **ARV-806**: KRAS G12D degrader for solid tumors, with rapid enrollment in clinical trials [128] - **ARV-393**: BCL6 degrader in phase 1 studies for B-cell and T-cell lymphomas, showing early responses [142][143] - **ARV-027**: Polyglutamine repeat AR degrader for Kennedy's disease, recently started in clinical trials [145] - **ARV-6723**: HPK1 degrader planned for future clinical use [146] Competitive Advantages - **PROTAC Technology**: - Allows for iterative degradation, overcoming resistance mechanisms that traditional inhibitors face [27][28] - Offers oral bioavailability and the ability to cross the blood-brain barrier, which is advantageous for treating neurodegenerative diseases [28] - **Differentiation**: Each program is focused on demonstrating unique benefits over existing therapies, such as improved efficacy and reduced resistance [20][21] Market Position and Strategy - **Commercialization**: Arvinas is seeking a new partner for the commercialization of vepdegestrant while focusing resources on earlier pipeline assets [18][19] - **Combination Therapies**: Emphasis on developing combination strategies, particularly for oncology applications, to enhance treatment efficacy [139] Clinical Insights - **LRRK2 and Neurodegeneration**: - Targeting LRRK2 is crucial for diseases like Parkinson's and progressive supranuclear palsy, with a goal to reduce LRRK2 levels by 50% to halt disease progression [81][82] - Preclinical data supports the potential for ARV-102 to impact pathologic proteins associated with these diseases [41][42] - **KRAS G12D**: - The ARV-806 program aims to demonstrate superior efficacy compared to existing inhibitors, with a focus on overcoming compensatory upregulation seen in traditional therapies [119][120] Upcoming Milestones - **Data Releases**: Anticipated data from ongoing trials, including results from ARV-102 in Parkinson's disease patients and updates on ARV-806 [68][128] - **Phase 1b Trial**: Plans to initiate a phase 1b trial for progressive supranuclear palsy by mid-year [68] Conclusion - Arvinas is positioned as a leader in the development of PROTAC degraders, with a robust pipeline and strategic focus on differentiation and combination therapies. The company is actively pursuing partnerships and preparing for significant clinical data releases in the near future.

Summary of Arvinas Conference Call Company Overview - Arvinas is a leader in protein degradation technology, focusing on PROTAC degraders to target disease-causing proteins [3][2] - The company has been operational for over 10 years and is currently advancing multiple programs in clinical trials [3] Current Clinical Programs Phase 1 Programs - Arvinas has four active Phase 1 programs: 1. **LRRK2 Degrader** for neurodegeneration, particularly targeting Parkinson's disease [2] 2. **KRAS G12D Degrader** for solid tumors [2] 3. **BCL6 Degrader (ARV-393)** for hematological cancers [2] 4. A newly initiated **AR Degrader (ARV-027)** targeting polyglutamine repeat AR associated with Kennedy's disease [22][2] LRRK2 Program - The LRRK2 degrader is in two Phase 1 studies, with data readouts expected at the ADPD conference [9][12] - Initial data from healthy volunteers showed the ability to cross the blood-brain barrier and reduce LRRK2 levels in cerebrospinal fluid (CSF) [11][12] - The program aims to expand into progressive supranuclear palsy (PSP) based on genetic and biomarker evidence [19] ARV-393 (BCL6 Degrader) - The BCL6 program is in Phase 1 dose escalation, with initial responses observed in both B-cell and T-cell lymphomas [39] - The program aims to demonstrate superior efficacy through degradation rather than inhibition, as BCL6 is rapidly resynthesized [40] KRAS G12D Program (ARV-806) - The KRAS G12D program has completed enrollment in its Phase 1 trial, with initial data expected in 2026 [57][58] - Preclinical data suggests a 25-fold increase in effectiveness compared to traditional inhibitors, with a focus on reducing Myc and enhancing apoptotic markers [62][64] Partnerships and Commercialization - Arvinas is working with Pfizer to secure a commercialization partner for vepdegestrant, with expectations to finalize by early June [34][35] - The company is exploring alternative options if a partner is not secured before the PDUFA date [37] Strategic Focus - The company emphasizes differentiation in its clinical programs, aiming to bring unique and effective therapies to market rather than competing with existing options [80] - Future data updates will focus on LRRK2, KRAS, and ARV-393, with a commitment to responsible capital deployment [82][66] Market Position and Outlook - Arvinas is positioned strongly within the competitive landscape of oncology and neurodegeneration, with a robust pipeline and proven technology platform [83] - The company aims to leverage its unique PROTAC technology to address unmet medical needs and enhance patient outcomes [83]

Arvinas Inc. (NASDAQ:ARVN) is one of the best cancer stocks to invest in now. On February 24, Arvinas Inc. (NASDAQ:ARVN) delivered solid fourth-quarter and full-year results that affirmed progress across pipeline development. Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials During the year, the company submitted its first new drug application, setting the stage for potential FDA approval of a PROTAC degrader. The company has already presented topline results for ARV-806, a ...

Drug Development and Clinical Trials - The FDA has accepted the New Drug Application for vepdegestrant, with a Prescription Drug User Fee Act action date set for June 5, 2026[691]. - Seven programs utilizing the PROTAC platform have progressed to clinical trials in oncology and neurology over the past five years[691]. - ARV-806 demonstrated in preclinical studies approximately 25 times greater in vitro potency than KRAS inhibitors and over 90% degradation for seven days after a single dose[702]. - ARV-102 showed substantial reduction of LRRK2 in cerebrospinal fluid with a promising safety profile during Phase 1 trials[697]. - The Phase 1 clinical trial of ARV-393 in patients with relapsed or refractory non-Hodgkin lymphoma has shown multiple responses in early cohorts[708]. - ARV-027 achieved 40-60% reductions in muscle monomeric polyQ-AR levels and improved muscle grip strength in preclinical studies[709]. - The company plans to present data from the multiple dose cohort of the Phase 1 clinical trial of ARV-102 in patients with Parkinson's disease in Q1 2026[699]. - Enrollment in the Phase 1 clinical trial of ARV-806 for patients with advanced solid tumors harboring KRAS G12D mutations is ongoing, with initial clinical data expected in 2026[704]. - The company has initiated a first-in-human Phase 1 clinical trial for ARV-027 in healthy volunteers in Q1 2026[710]. - The ongoing clinical trials of vepdegestrant in collaboration with Pfizer include a study lead-in for patients with first-line metastatic breast cancer[713]. - In Q1 2025, the company and Pfizer announced positive topline results from the Phase 3 VERITAC-2 clinical trial for vepdegestrant in the ESR1m population[715]. - The NDA for vepdegestrant was submitted to the FDA in Q2 2025, marking the first NDA for a PROTAC, with a PDUFA date set for June 5, 2026[716]. - In Q2 2025, the company and Pfizer presented PRO data from the VERITAC-2 trial, showing vepdegestrant reduced the risk of deterioration in several health domains compared to fulvestrant[717]. - The company removed two planned Phase 3 combination trials of vepdegestrant from the joint development plan with Pfizer in Q2 2025[718]. - The company plans to initiate a Phase 1 clinical trial for ARV-6723 in mid-2026, targeting advanced solid tumors[725]. - The company plans to present preclinical data for its pan-KRAS program in Q1 2026, demonstrating robust activity against multiple KRAS variants[726]. Financial Performance and Revenue - The company has not generated any revenue from product sales to date and continues to incur significant operating losses[736]. - In 2025, the company received a development milestone payment of $20.0 million under the Novartis License Agreement, with total contingent payments from this agreement potentially reaching $1.01 billion[753]. - The Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer includes an upfront payment of $650 million and potential additional payments of up to $1.4 billion based on regulatory and sales milestones[743]. - Revenue for the year ended December 31, 2025 was $262.6 million, down from $263.4 million in 2024, primarily due to a decrease of $162.4 million from the Novartis License Agreement[792]. - Other income for 2025 was $38.0 million, down from $51.9 million in 2024, reflecting a decrease of $13.9 million[790]. - The net loss for the year ended December 31, 2025 was $80.8 million, significantly improved from a net loss of $198.9 million in 2024, an improvement of $118.1 million[790]. - Cash, cash equivalents, and marketable securities totaled $685.4 million as of December 31, 2025, down from $1.0 billion in 2024[808]. - Net cash used in operating activities increased to $273.8 million in 2025 from $259.3 million in 2024, an increase of $14.5 million[809]. - Net cash provided by investing activities increased significantly to $407.6 million in 2025, up from $34.7 million in 2024, an increase of $372.9 million[812]. - Net cash used in financing activities decreased to $91.4 million in 2025 from $7.9 million in 2024, a decrease of $99.3 million[814]. Cost Management and Operational Changes - The company announced a workforce reduction of approximately 33% in April 2025 to streamline operations and reduce costs, with completion by the end of Q2 2025[732]. - Restructuring charges of $3.7 million were recognized, with expected annual operating cost savings of $100 million on a run-rate basis[734]. - Total research and development expenses for the year ended December 31, 2025, amounted to $285.2 million, a decrease from $348.2 million in 2024 and $379.7 million in 2023[765]. - Program-specific external expenses for Vepdegestrant (ARV-471) were $62.7 million in 2025, down from $76.9 million in 2024 and $104.8 million in 2023[765]. - Research and development expenses for the year ended December 31, 2025 totaled $285.2 million, a decrease of $63.0 million from $348.2 million in 2024[793]. - Non-GAAP research and development expenses for 2025 were $252.2 million, compared to $298.5 million in 2024, excluding restructuring and stock-based compensation expenses[795]. - General and administrative expenses for 2025 were $95.9 million, a decrease of $69.5 million from $165.4 million in 2024[790]. - General and administrative expenses decreased to $95.9 million for the year ended December 31, 2025, down from $165.4 million in 2024, a reduction of $69.5 million[796]. - Non-GAAP general and administrative expenses for 2025 totaled $71.2 million, compared to $126.9 million in 2024, reflecting a decrease of $55.7 million[797]. - The company expects general and administrative expenses to increase in the future due to the need for additional personnel and compliance costs associated with being a public company[771]. Future Outlook and Funding Needs - The company expects to incur significant expenses related to ongoing preclinical and clinical activities, including managing employees and retaining key talent[737]. - The company may need to obtain substantial additional funding for its operations, as it does not expect to generate revenue from product sales in the near future[738]. - The company anticipates significant increases in expenses as it continues clinical trials and develops product candidates, including ARV-102 and ARV-806[820]. - The company expects its cash resources to fund operations into the second half of 2028, but may require substantial additional financing to continue operations[821]. - The company borrowed $2.0 million under the 2018 Assistance Agreement, with $1.0 million forgiven upon meeting employment conditions[825]. - The outstanding debt under the 2018 Assistance Agreement was $0.6 million as of December 31, 2025, with a fixed interest rate of 3.25% per annum[826]. - The 2018 Assistance Agreement requires the company to remain located in Connecticut through September 2028, with penalties for default[826]. Collaboration and Strategic Partnerships - Collaboration success with partners like Pfizer and Genentech is crucial for the company's development programs[825]. - The company aims to establish additional collaboration arrangements with other biotechnology or pharmaceutical companies[825]. - The company is focused on the costs and timing of regulatory reviews for its product candidates[825]. - Future commercialization activities will involve costs related to manufacturing, marketing, sales, and distribution[825].

Financial Data and Key Metrics Changes - The company reported $9.5 million in revenue for Q4 2025, a significant decrease from $59.2 million in Q4 2024, primarily due to a $40.3 million decline in revenue from the Novartis license agreement [19] - For the full year 2025, total revenue was $262.6 million, slightly down from $263.4 million in 2024 [19] - Cash equivalents and marketable securities at the end of Q4 2025 were just over $685 million, down from over $1 billion at the end of 2024 [18] Business Line Data and Key Metrics Changes - The company has four ongoing clinical trials across oncology and neurology, including the first-in-human trial of ARV-027, a polyQ-AR degrader [5] - ARV-102, a LRRK2 degrader, has shown over 50% reduction in LRRK2 in the CSF of healthy volunteers, indicating strong brain penetration [27] - ARV-806, targeting KRAS G12D, has demonstrated over 25-fold potency in reducing cancer cell proliferation compared to existing therapies [30] Market Data and Key Metrics Changes - The company is focusing on developing differentiated treatments in competitive areas, with a strong emphasis on clinical data to validate their approach [36] - The competitive landscape includes multiple programs targeting similar pathways, necessitating clear differentiation for success [36] Company Strategy and Development Direction - The company aims to maximize opportunities in core areas by focusing on differentiated treatments that provide significant patient benefits [10] - A strategic refocus on Phase I clinical programs has been implemented, with a commitment to only advance treatments that demonstrate clear differentiation [10] - The company plans to initiate a Phase 1B trial for ARV-102 in PSP and potentially a registrational trial by late 2026 [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong pipeline and financial position, anticipating multiple data readouts and clinical advancements in 2026 [4][23] - The company is committed to developing treatments that do not compromise on efficacy, safety, and tolerability, aiming for transformative impacts on patient care [10] Other Important Information - The company has suspended its stock repurchase program after buying back approximately 10 million shares for a total of $91.9 million [22] - Discussions with potential partners for the commercialization of vepdegestrant are ongoing, with expectations to finalize an agreement before the June 5th PDUFA date [9][72] Q&A Session Summary Question: What key data will determine if a program is differentiated? - Management indicated that differentiation will vary by program, with specific data points needed for each to establish superiority over competitors [34][36] Question: What should be expected from ARV-102 data at ADPD? - Management noted that the data will focus on safety and efficacy in Parkinson's patients, with expectations of demonstrating continued safety and biomarker engagement [49][50] Question: Will there be any dose modifications needed for ARV-393 in combination with glofitamab? - Management does not anticipate needing dose modifications but will proceed with caution and evaluate during the combination studies [63] Question: What are the early observations for ARV-393? - Early data show responses in patients with B and T cell lymphomas, with good degradation of BCL6, supporting continued development [85] Question: What is the strategy for the polyQ-AR degrader? - The company is exploring surrogate markers for SBMA and engaging with health authorities for potential future studies [89]